Sepragen.com

Home | Contact Us 


Online Catalog


View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at sales@sepragen.com.



How Can We Help You?
Click here to contact us!

 



Sepragen Corporation Receives ‘Notice Of Allowance’ For Two Additional Patents

HAYWARD, CA, February 15, 2000 - Sepragen Corporation (OTC BB: SPGNU, SPGNA, SPGNW) today announced the allowance of two new patent applications stemming from its core separation technology, bringing the total number of patents on its platform technology and related applications to 16.

The first of the latest two allowances relates to the Sepralac® Process for extracting high value nutritional proteins from cheese whey for use in infant formula and sports nutrition food and beverage products. The second relates to the SepraDebitt® Process for removing bitterness and acidity from citrus juices such as grapefruit and orange juice.

Vinit Saxena, Chairman and CEO of Sepragen commented, “Sepragen now has 14 patents and 2 allowed patents to protect our platform separation technology and the many processes and components that allow large scale applications and commercialization.” He added, “We have recently begun commercialization of our Sepralac® Process through licensing arrangements with two internationally recognized dairy suppliers and we are aggressively pursuing agreements along all of our patented applications.”

Sepragen Corporation develops and markets technology along with equipment and supplies for process chromatography applications. Sepragen has developed a number of patented applications that provide large market opportunities in the food and beverage industry, including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as well as extracting proteins from whey. The company holds over 14 issued patents relating to its core technology.

Return to News Archives main page



The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.


Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2018 Sepragen Corporation. All rights reserved. (510) 475-0650